Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Reports & Briefings
In May 2016 the ‘Review on Antimicrobial Resistance’, commissioned by the government of the United Kingdom and the Welcome Trust, was published by the AMR Review team lead by lord Jim O'Neill. The review set out nine broad recommendations for government intervention to tackle antimicrobial resistance (AMR).
Last updated 22 July 2016
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expanding access to affordable antiretroviral therapy (ART).
Last updated 15 July 2016
From 2013-2016 the UNITAID-funded MSF HIV viral load initiative has supported the programmatic and/or laboratory scale-up of viral load testing in seven countries (DRC, Lesotho, Malawi, Mozambique, Swaziland, Uganda and Zimbabwe) performing almost 320,000 viral load tests. The three years of implementation have seen both laboratory and programmatic strategies developed to enhance the uptake of routine viral load. Success withstanding, significant challenges still remain.
Last updated 8 July 2016
The Regional Comprehensive Economic Partnership (RCEP) is a regional trade agreement being negotiated between the 10 ASEAN (Association of Southeast Asian Nations) countries and Australia, China, India, Japan, New Zealand and South Korea. In terms of impact, RCEP will cover nearly 50% of the world’s population – including the most impoverished, vulnerable and marginalized people living in the Least Developed Countries (LDCs).
Last updated 13 June 2016
Time to align medical research and development with people’s health needs Every day, MSF staff confront significant gaps in the availability of medical tools to address the health needs of the people we aim to care for, in crisis-affected communities in more than 60 countries. These gaps – which have persisted for as long as MSF has been in operation – contribute to preventable deaths and exacerbate ongoing humanitarian and medical crises.
Last updated 29 April 2016
According to the World Health Organization, the number of malaria deaths has fallen globally from 839,000 in 2000 to 438,000 in 2015. This is partly due to the scale up of artesunate-based combination therapies and specifically the use of injectable artesunate for the most severe forms of the disease. However, there are still many malaria deaths because patients simply cannot reach a health care center, where these injections can be administered, quickly enough.
Last updated 25 April 2016
Out of Focus: How millions of people in West and Central Africa are being left out of the global HIV response
This report aims to highlight the shortfalls in policy and practices for people living with HIV in West and Central Africa countries that face significant treatment gaps. It points to key obstacles to boosting antiretroviral treatment coverage in West and Central Africa, focusing on contexts where MSF is involved in the HIV response. It brings together the experience of MSF teams, including data from local pilot projects, small-scale patient data collection, patient surveys and other programmatic information.
The ‘3P Project’ aims to rapidly deliver affordable, effective new regimens for TB through an open collaborative approach to conducting drug development and through novel approaches to financing and coordinating R&D. The 3P Project implements three mechanisms to facilitate the necessary and appropriate R&D for TB regimens:
Last updated 29 March 2016
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.
Last updated 21 March 2016
138th WHO EB - Briefing - “From Ebola and Beyond: faulty governance of the health system in responding to medical emergencies and epidemics- Agenda Item 5 & 8.4
Despite affordable preventive measures and available treatments, epidemic outbreaks of measles, malaria, cholera, and meningitis recur every year, often with devastating consequences for people in less developed countries. At the same time, outbreaks of lesser-known or emerging diseases are declared in new areas of the globe. Generally, infectious diseases tend to be under-reported and therefore the health response remains insufficient, posing a greater threat to people’s health.
Last updated 25 January 2016